Browse SELL

Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF00059 Lectin C-type domain
PF00084 Sushi repeat (SCR repeat)
Function

Calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells (PubMed:12403782, PubMed:28489325, PubMed:28011641). Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. Promotes initial tethering and rolling of leukocytes in endothelia (PubMed:12403782, PubMed:28011641).

> Gene Ontology
 
Biological Process GO:0014074 response to purine-containing compound
GO:0033198 response to ATP
GO:0046683 response to organophosphorus
GO:0050900 leukocyte migration
Molecular Function GO:0002020 protease binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0030246 carbohydrate binding
GO:0043208 glycosphingolipid binding
GO:0046625 sphingolipid binding
GO:0050839 cell adhesion molecule binding
GO:0051861 glycolipid binding
GO:1901681 sulfur compound binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SELL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SELL and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19658092FibrosarcomaPromote immunity (T cell function)HP of CD8(+) T cells is dependent on host IL-7, IL-15, and MHC-class I and has been shown to prevent T-cell tolerance, reverse T-cell anergy and support T-cell-mediated tumor control in vivo. Since we observed that the earliest detectable HP occurs within LN and that T cells undergoing HP retain a CD62L(bright) phenotype, we investigated the functional role of CD62L for this process. We found that CD62L-expression on T cells is required for optimal HP and HP was impaired in lymphotoxin-alphabeta(-/-) mice, indicating the necessity for intact host secondary lymphoid organ structures.
29104081Colon CacinomaPromote immunityAdditionally, TWS119 can induce the expression of CD62L or CCR5 to generate a population of CD62L+γδT or CCR5+γδT cells in a dose-dependent manner.
25164013breast carcinoma; colon carcinoma; melanoma; colon adenocarcinoma; prostate carcinomaPromote immunity(T cell function)Furthermore, HMGB1 increased MDSC-mediated production of IL-10, enhanced crosstalk between MDSCs and macrophages, and facilitated the ability of MDSCs to downregulate expression of the T-cell homing receptor L-selectin
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SELL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SELL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3140.559
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4910.711
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1690.89
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3770.489
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0340.98
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9020.605
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8050.211
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7380.612
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.950.536
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.9910.158
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.290.582
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0850.712
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SELL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SELL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SELL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SELL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SELL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SELL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SELL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSELL
Nameselectin L
Aliases LSEL; LAM1; LAM-1; hLHRc; Leu-8; Lyam-1; PLNHR; CD62L; LYAM1; LNHR; lymphocyte adhesion molecule 1; LECAM1; ......
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SELL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.